NINTEDANIB: EFFECTS ON EXTRACELLULAR MATRIX TURNOVER BIOMARKERS IN IDIOPATHIC PULMONARY FIBROSIS

被引：0

作者：

Jo, H. ^{[1
]}

Maher, T. ^{[2
,3
]}

Stowasser, S. ^{[4
]}

Nishioka, Y. ^{[5
]}

White, E. ^{[6
]}

Cottin, V ^{[7
]}

Noth, I ^{[8
]}

Selman, M. ^{[9
]}

Wachtlin, D. ^{[10
]}

Diefenbach, C. ^{[11
]}

Jenkins, R. ^{[12
]}

机构：

[1] Royal Prince Alfred Hosp, Dept Resp Med, Sydney, NSW, Australia

[2] Royal Brompton & Harefield NHS Fdn Trust, Natl Inst Hlth Res Resp Biomed Res Unit, London, England

[3] Imperial Coll, Fibrosis Res Grp, Natl Heart & Lung Inst, London, England

[4] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[5] Tokushima Univ, Grad Sch Biomed Sci, Tokushima, Japan

[6] Univ Michigan, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA

[7] Claude Bernard Univ Lyon 1, Louis Pradel Hosp, Lyon, France

[8] Univ Chicago, Pulm & Crit Care Med, Chicago, IL 60637 USA

[9] Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico

[10] Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim, Germany

[11] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[12] Univ Nottingham, City Hosp, Nottingham, England

来源：

RESPIROLOGY | 2019年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

TP 120

引用

页码：169 / 169

页数：1

共 50 条

[1] Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study
Maher, Toby M.
Stowasser, Susanne
Nishioka, Yasuhiko
White, Eric S.
Cottin, Vincent
Noth, Imre
Selman, Moises
Rohr, Klaus B.
Michael, Andreas
Ittrich, Carina
Diefenbach, Claudia
Jenkins, R. Gisli
LANCET RESPIRATORY MEDICINE, 2019, 7 (09): : 771 - 779
[2] Pivotal Role of Matrix Metalloproteinase 13 in Extracellular Matrix Turnover in Idiopathic Pulmonary Fibrosis
Nkyimbeng, Takwi
Ruppert, Clemens
Shiomi, Takayuki
Dahal, Bhola
Lang, Gyoergy
Seeger, Werner
Okada, Yasunori
D'Armiento, Jeanine
Guenther, Andreas
PLOS ONE, 2013, 8 (09):
[3] Nintedanib for Idiopathic Pulmonary Fibrosis
Tepede, Abisola
Yogaratnam, Dinesh
JOURNAL OF PHARMACY PRACTICE, 2019, 32 (02) : 199 - 206
[4] NINTEDANIB IN IDIOPATHIC PULMONARY FIBROSIS
Woodcock, H. V.
Maher, T. M.
DRUGS OF TODAY, 2015, 51 (06) : 345 - 356
[5] Nintedanib in idiopathic pulmonary fibrosis
Venkatesan, Priya
LANCET RESPIRATORY MEDICINE, 2021, 9 (11): : E108 - E108
[6] Extracellular matrix biomarkers predict change in lung function in idiopathic pulmonary fibrosis
Jessen, Henrik
Hoyer, Nils
Ronnow, Sarah
Karsdal, Morten
Leeming, Diana
Sand, Jannie
Shaker, Saher
EUROPEAN RESPIRATORY JOURNAL, 2020, 56
[7] Extracellular matrix remodeling in idiopathic pulmonary fibrosis
Pardo, A
Selman, M
CHEST, 2001, 120 (01) : 77S - 77S
[8] Nintedanib for the Idiopathic Pulmonary Fibrosis with Emphysema
Krome, Susanne
PNEUMOLOGIE, 2019, 73 (03):
[9] Nintedanib for the treatment of idiopathic pulmonary fibrosis
Varone, Francesco
Sgalla, Giacomo
Iovene, Bruno
Bruni, Teresa
Richeldi, Luca
EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (02) : 167 - 175
[10] Nintedanib in the treatment of idiopathic pulmonary fibrosis
Mazzei, Mariano E.
Richeldi, Luca
Collard, Harold R.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (03) : 121 - 129

← 1 2 3 4 5 →